NCT03919292View on ClinicalTrials.gov

Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

May 1, 2019

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2027

Conditions
Solid Tumor, Adult
Interventions
DRUG

Neratinib

Combination of Neratinib and Divalproex Sodium (Valproate) will be given to patients with advanced solid tumors (dose escalation) and Ras-mutated cancers (dose expansion). Doses of Neratinib are escalated in small groups of patients during the dose expansion portion of the study.

DRUG

Divalproex Sodium

Combination of Neratinib and Divalproex Sodium (Valproate) will be given to patients with advanced solid tumors (dose escalation) and Ras-mutated cancers (dose expansion).

Trial Locations (1)

23298

RECRUITING

Virginia Commonwealth University Massey Cancer Center, Richmond

All Listed Sponsors
collaborator

Puma Biotechnology, Inc.

INDUSTRY

lead

Virginia Commonwealth University

OTHER